Results 71 to 76 of about 8,016 (76)

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study

Journal of Clinical Oncology, 2013
Guillaume Cartron, Catherine Thieblemont
exaly  

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

Leukemia, 2018
Paula Cramer, Petra Langerbeins, Anna-Maria Fink   +2 more
exaly  

GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption

Dermatology and Therapy, 2012
exaly  

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study

Blood, 2011
Laurie H Sehn, Andre H Goy, Giovanni Martinelli   +2 more
exaly  

CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101

Blood, 2011
Wouter Kallemeijn, Christian Klein, René A W Van Lier   +2 more
exaly  

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non‐Hodgkin's Lymphoma and Exposure–Response in CLL

CPT: Pharmacometrics and Systems Pharmacology, 2014
exaly